We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Epstein-Barr Virus Increases Risk of MS

By LabMedica International staff writers
Posted on 15 Sep 2017
While being infected at a young age with Epstein-Barr virus generally causes few, if any, symptoms, delayed exposure into adolescence or adulthood can cause infectious mononucleosis with symptoms that can be quite severe.

Caucasians, Hispanics and African-Americans who have had infectious mononucleosis, commonly known as mono, which is caused by Epstein-Barr virus, may have an increased risk of multiple sclerosis (MS). More...
Independent of other factors that could affect MS risk, such as sex, age, smoking and genetic ancestry, the risk of MS for those who had mono was higher than for those who had not.

A team of scientists working with those at Kaiser Permanente Southern California (Pasadena, CA, USA) recruited 1,090 African-Americans, Hispanic and white people, over a three-year period, with each group having a near balance of healthy people to people with MS or its precursor, called clinically isolated syndrome. Participants had blood tests to check for the Epstein-Barr virus antibody and were asked whether they had ever had mono. Incident cases of MS or its precursor, clinically isolated syndrome (CIS), and matched controls (African-Americans, 111 cases/128 controls; Hispanics, 173/187; whites, 235/256) were included in the study.

Epstein-Barr nuclear antigen-1 (EBNA-1) seropositivity was independently associated with an increased odds of MS/CIS in all three racial/ethnic groups. In contrast, cytomegalovirus (CMV) seropositivity was associated with a lower risk of MS/CIS in Hispanics, but not in blacks or whites. Among African-Americans, 12/111 (11%)of the people with MS, , had mono in the past, compared to 4/128 people who did not have MS,(3%). For Hispanics, 13/173 people (8%) with MS, had mono in the past, compared to 3/187 people (2%) who did not have MS.. Among whites, 48/235 (20%) people with MS, had mono in the past, compared percent to 30/256 people (12%), of those without the disease.

The authors concluded that The consistency of EBNA-1 seropositivity with MS across racial/ethnic groups and between studies points to a strong biological link between EBV infection and MS risk. The association between past CMV infection and MS risk supports the broader hygiene hypothesis, but the inconsistency of this association across racial/ethnic groups implies non-causal associations.

Annette Langer-Gould, MD, PhD, the lead author of the study, said, “While many people had Epstein-Barr virus antibodies in their blood, we found among all three groups, people who also developed mono in their teen years or later had a greater risk of MS. This implies that delaying Epstein-Barr virus infection into adolescence or adulthood may be a critical risk factor for MS.” The study was published on August 30, 2017, in the journal Neurology.

Related Links:
Kaiser Permanente Southern California


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.